Cadila Pharmaceuticals collaborates with NovaSAID to develop drugs for Arthritis

Cadila Pharmaceuticals, based in Ahmedabad, Gujarat, India announced a strategic partnership and tie up with Sweden based firm, NovaSAID AB,research based company developing compounds for treatment of inflammatory pain and conditions like Rheumatoid Arthritis in Karolinska Development, with the aim of developing new treatment methods for inflammation and pain noticed in disorders such as Rheumatoid Arthritis. Based on the agreement, all the revenue that will be generated from the sale as well as marketing of products in countries such as India, Africa and Middle East will be retained by Cadila Pharmaceuticals and the net sale in the other countries and locations will be shared by both.

Both the companies have collaborated for the development of preclinical as well as clinical drugs. The drug candidates are developed by NovaSAID at Cadila Pharmaceuticals' facility located in Ahmedabad. As part of the partnership, Cadila Pharmaceuticals will be bearing all the costs that will be associated with the development program through to Phase II. According to TorbjornBjerke, Chief Executive Officer, Karolinska Development, this particular partnership and collaboration offers an opportunity to the shareholders of NovaSAID to take the organisation ahead with availability of great resources and incurring no further costs. Furthermore, the expertise of drug development of Cadila Pharmaceuticals matches with the scientific excellence of NovaSAID. This provides a solid platform to develop more superior and novel drugs. The successful development of such drugs will open up opportunities of striking major and valuable deals in USA and European territories for the benefit of Karolinska Development's shareholders.

Rajiv I Modi, Chairman and Managing Director, Cadila Pharmaceuticals remarked in agreement with TorbjornBjerke that this partnership will combine scientific expertise of NovaSAID and the drug capabilities of Cadila Pharmaceuticals will work towards creating new and novel solutions in the treatment process attending to patients suffering from pain and inflammation which require therapies to a great extent. This drug will add value to the track record of Cadila Pharmaceuticals other innovative drugs such as Polycap (five in one pill for prevention and treatment of cardiac diseases), Risorine (an innovative treatment solution for Tuberculosis) and Mycidac-C (world's first active immunotherapy drug for treatment of lung cancer.

Regarding the development of a drug that is aimed at making treatment of Rheumatoid Arthritis and other inflammation and pain related disorders, the idea is to reduce the risks of side effects such as myocardial infarction and gastric ulcers that often takes place with the intake of the other drugs. NovaSAID's drug candidates will target inclusion of an enzyme called microsomal prostaglandin E synthase-1 (mPGES-1) which is a critically important mediator of pain and inflammation and is known to reduce such side effects theoretically. Per-Johan Jakobsson, Co-Founder and Board Director, NovaSAID and Associate Professor, Karolinska Institutet added, mPGES-1 constitutes an important target for drug discovery and development of analgetic as well as anti-inflammatory drug. Apart from being used for treatment of chronic inflammatory diseases, the effective enzyme inhibitors may also address a broad range of other diseases with concomitant inflammation such as atherosclerosis, stroke and cancer.

Active Pharmaceutical Ingredients- License Requirements for Indian Drug Exporters

Active pharmaceutical ingredients are those components present in drugs due to which medications work. Though it is far from being such a simple thing and process as it sounds. There are a series of regulations and laws that surround everything regarding API and license laws are just the beginning. Read on to know more of these laws related to the license requirements. There are certain documents that should be submitted for Import and Registration of API or Bulk Drugs in India.

An application has to be submitted in three or more files along with

-          Covering letter- It would include your intention of application. Specify clearly your requirement. Whether you are applying for registration of manufacturing site, for license, renewal or re-registration etc- it should be mentioned along with proper papers to support your intent. The documents list should be mentioned in form of index along with page numbers. If you need to provide the authorities with some more information, it has to be here in the covering letter. Also, if you are not providing any document, it should be mentioned here. Finally, this letter must be signed and stamped by proper authorities on the firm’s letterhead, along with its name and designation.

-          Authorizing letter- According to Rule 122 A, an original letter has to be submitted, issued by the Company Secretary, Director or partner which will carry name, signature and designation of the person who is authorized to sign in the legal papers like Power of Attorney, Form 40 etc. Validity of this document will be as per the policies of the company. When submitting subsequent applications within this valid period, self-attested photocopies of the Authorization Letter should be attached.

-          Drugs and Cosmetic Rules have a format and it should be followed when filling up Form 40. It must be stamped and signed by the local agent or manufacturer whoever is authorized and has valid license to do business in India.

-          Power of Attorney- When a foreign based company wishes to register and apply for license in India, it has to authorize an agent here in this country. This authorization is done by the means of a document of Power of Attorney, which is executed as well as authenticated in two ways- in front of a first class Magistrate in India or in front of a similar authority in the origin country. In later case, the document has to be attested by the Indian Embassy in that country. The original copy of this document has to be attached along with the application form. This authorized person would be the sole responsible one for any activity undertaken by the company in India. The performa for the Power of Attorney can be obtained from Annexure III.

Before applying, documents should be kept ready and up to date. For any kind of license and registration certificate, it is very important to maintain the standard of API because it is the ultimate 

Cadila Pharmaceuticals believes in “Collaborative indigenous effort is key to R&D success”

Cadila Pharmaceuticals Limited believes and works towards providing affordable healthcare to all. In order to achieve the same, it has always taken steps to remain ahead of time and keep innovating products that are beyond its generic nature. In order to offer different pharmaceutical products addressing different problems, Cadila Pharmaceuticals has addressed many key areas in modern medicine.

The mission and goal of Cadila Pharmaceuticals is to produce and provide affordable medicines to the common people that was first established by the company’s founder Chairman Shri I A Modi. The basic aim is to offer innovative as well as the world’s first molecule at an affordable price. Drugs such as Risorine, Polycap or Mycidac C are such examples that describes the organisation’s commitment to the cause of offering affordable and cost-effective drugs and medicines to people.

A major breakthrough in 2009 took place as with the launch of Polycap, a drug that helps in preventing cardiovascular diseases. This is a novel drug that has a combination of three antihypertensive drugs along with aspirin and a statin (cholesterol lowering drug). The R&D team, in the very same year, also made a major discovery in the field of tuberculosis as they produced and launched Risorine. This is the first boosted rifampicin that contains a fixed dose combination to be used as an anti-tuberculosis drug.

In 2013, Cadila Pharmaceuticals achieved another milestone with the launch of Mycidac C that is used for treatment of lung cancer. This is also the first active immunotherapy drug in the world used for treatment of lung cancer.

For Cadila Pharmaceuticals, R&D has always been a focus area and an investment of six to seven percent from the total revenue is done on the same. The state-of-the-art in house R&D facility has over 350 scientists who works towards producing many such drugs and medicines that are known to be the world’s firsts and can be made available for the people at an affordable price.

Cadila Pharmaceuticals is also known to invest in development of innovative products such as vaccines, pain management drugs and antibiotics and many other drugs. In their joint venture with Novavax, the focus has been on development of new vaccine candidates using virus like particle (VLP) technology. The organisation has also tied up with NovaSAID based out of Sweden in order to develop innovative treatment medicines to address inflammation related problems as well as to manage pain. Cadila Pharmaceuticals’ strategic collaboration with Pergamum AB is aimed at development of a novel treatment for infections with a unique targeting mechanism that is clearly distinguished from the other groups of antibiotics. 

Cadila Pharmaceuticals collaborates with NovaSAID to develop drugs for Arthritis

CadilaPharmaceuticals, based in Ahmedabad, Gujarat, India announced a strategic partnership and tie up with Sweden based firm, NovaSAID AB,research based company developing compounds for treatment of inflammatory pain and conditions like Rheumatoid Arthritis in Karolinska Development, with the aim of developing new treatment methods for inflammation and pain noticed in disorders such as Rheumatoid Arthritis. Based on the agreement, all the revenue that will be generated from the sale as well as marketing of products in countries such as India, Africa and Middle East will be retained by Cadila Pharmaceuticals and the net sale in the other countries and locations will be shared by both.

Both the companies have collaborated for the development of preclinical as well as clinical drugs. The drug candidates are developed by NovaSAID at Cadila Pharmaceuticals' facility located in Ahmedabad. As part of the partnership, Cadila Pharmaceuticals will be bearing all the costs that will be associated with the development program through to Phase II. According to TorbjornBjerke, Chief Executive Officer, Karolinska Development, this particular partnership and collaboration offers an opportunity to the shareholders of NovaSAID to take the organisation ahead with availability of great resources and incurring no further costs. Furthermore, the expertise of drug development of Cadila Pharmaceuticals matches with the scientific excellence of NovaSAID. This provides a solid platform to develop more superior and novel drugs. The successful development of such drugs will open up opportunities of striking major and valuable deals in USA and European territories for the benefit of Karolinska Development's shareholders.

Rajiv I Modi, Chairman and Managing Director, Cadila Pharmaceuticals remarked in agreement with TorbjornBjerke that this partnership will combine scientific expertise of NovaSAID and the drug capabilities of Cadila Pharmaceuticals will work towards creating new and novel solutions in the treatment process attending to patients suffering from pain and inflammation which require therapies to a great extent. This drug will add value to the track record of Cadila Pharmaceuticals other innovative drugs such as Polycap (five in one pill for prevention and treatment of cardiac diseases), Risorine (an innovative treatment solution for Tuberculosis) and Mycidac-C (world's first active immunotherapy drug for treatment of lung cancer.

Regarding the development of a drug that is aimed at making treatment of Rheumatoid Arthritis and other inflammation and pain related disorders, the idea is to reduce the risks of side effects such as myocardial infarction and gastric ulcers that often takes place with the intake of the other drugs. NovaSAID's drug candidates will target inclusion of an enzyme called microsomal prostaglandin E synthase-1 (mPGES-1) which is a critically important mediator of pain and inflammation and is known to reduce such side effects theoretically. Per-Johan Jakobsson, Co-Founder and Board Director, NovaSAID and Associate Professor, Karolinska Institutet added, mPGES-1 constitutes an important target for drug discovery and development of analgetic as well as anti-inflammatory drug. Apart from being used for treatment of chronic inflammatory diseases, the effective enzyme inhibitors may also address a broad range of other diseases with concomitant inflammation such as atherosclerosis, stroke and cancer.

pharmaceutical companies in India,

Cadila Pharmaceuticals has a multicultural, multilingual and multinational workforce of more than seven thousand employees including over two hundred people outside India in Africa, CIS, Japan and USA.
Cadila Pharmaceuticals is also partnering for growth with leading international companies worldwide in the areas of vaccine development, biological therapeutics and diagnostics, stem cell banking and hospital management. The company has also strategic alliances for preventing in-patient infections and development of novel treatment for specific and acute infections, for developing Antibiotic Resistant Breakers and innovative treatment in inflammation and pain management.

`

More Detail visit Our Website - www.cadilapharma.com

Amlodipine API Manufacturers

Cadila Pharmaceuticals Limited is one of the foremost pharma companies in India synthesizing APIs. We are blood pressure bulk drug manufacturer of Amlodipine. The CAS number of Amlodipine is 88150-42-9.Amlodipine is used to cure high blood pressure. Reducing high blood pressure helps to prevent heart attack, stroke and kidney problems. Amlodipine is a calcium channel blocker drug. It relaxes blood vessels so blood can flow easily. It is also used to prevent certain types of chest pain. Cadila Pharmaceuticals Limited is one of the leading USFDA approved pharma companies based in India. It is regarded as a best Active Pharmaceutical Ingredients (APIs) manufacturing company in India. One of our main goals is to synthesize APIs of the supreme quality with reasonable price.

We are major blood pressure drug manufacturer and supplier. We are Amlodipine supplier to Asian countries like; Japan, China, Georgia, Singapore, Malaysia, Vietnam, South Korea etc., and Middle East countries like; UAE, Iran, Iraq, Egypt, Syria etc.


More Detail APIs - www.cadilapharma.com

.

Nebivolol Manufacturers In India